Popular Trials
Bruton's Tyrosine Kinase (BTK) Inhibitor
Acalabrutinib + Rituximab for Peripheral Neuropathy
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is researching whether combining these two drugs is safe and effective for treating people with IgM monoclonal gammopathy of undetermined significance or Waldenström macroglobulinemia-related neuropathies.
LOXO-338 for Blood Cancers
Recruiting1 awardPhase 1
Miami, Florida
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Acalabrutinib + Chemotherapy for Waldenstrom's Macroglobulinemia
Recruiting3 awardsPhase 2
Vancouver, British Columbia
This trial tests a combination of two established drugs and one new drug in untreated patients with a specific type of blood cancer. The treatment works by killing cancer cells, boosting the immune system, and blocking growth signals.
Popular Filters
Trials for WM Patients
Antibiotic
Rifaximin for Monoclonal Gammopathy
Recruiting3 awardsPhase 1
Atlanta, Georgia
This trial studies how well rifaximin, an oral antibiotic, works in treating patients with monoclonal gammopathy. It aims to reduce abnormal blood proteins or cells by killing intestinal bacteria. Rifaximin has been used successfully for CDI treatment but lacks United States Food and Drug Administration approval for this indication.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Oral LOXO-305 for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is testing pirtobrutinib, a tablet taken by mouth, in patients with certain types of blood cancers who haven't responded to or can't tolerate usual treatments. The medication works by blocking a protein that cancer cells need to grow. The study aims to find the best dose and see how well it works.
Enzyme Inhibitor
Ibrutinib + Ixazomib for Waldenstrom's Macroglobulinemia
Recruiting3 awardsPhase 2
Jacksonville, Florida
This trial looks at the side effects of two drugs, ibrutinib and ixazomib, when given together to treat Waldenstrom macroglobulinemia. Enzyme inhibitors, such as ibrutinib and ixazomib, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Stem Cell Transplant + Chemotherapy for Leukemia and Lymphoma
Recruiting1 awardPhase 1 & 2
Buffalo, New York
This trial is studying how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant.
BTK Inhibitor
Nemtabrutinib for Blood Cancers
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing a new pill called nemtabrutinib for patients with blood cancers that have returned or didn't respond to other treatments. The goal is to find a safe and effective dose of the drug. Nemtabrutinib is a new drug being tested for blood cancers, designed to reduce adverse effects.
Trials for Mantle Cell Lymphoma Patients
Bruton's Tyrosine Kinase (BTK) Inhibitor
Oral LOXO-305 for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is testing pirtobrutinib, a tablet taken by mouth, in patients with certain types of blood cancers who haven't responded to or can't tolerate usual treatments. The medication works by blocking a protein that cancer cells need to grow. The study aims to find the best dose and see how well it works.
Stem Cell Transplant + Chemotherapy for Leukemia and Lymphoma
Recruiting1 awardPhase 1 & 2
Buffalo, New York
This trial is studying how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant.
BTK Inhibitor
Nemtabrutinib for Blood Cancers
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing a new pill called nemtabrutinib for patients with blood cancers that have returned or didn't respond to other treatments. The goal is to find a safe and effective dose of the drug. Nemtabrutinib is a new drug being tested for blood cancers, designed to reduce adverse effects.
Radioisotope Therapy
Iopofosine for Waldenstrom Macroglobulinemia
Recruiting1 awardPhase 2
Redlands, California
This trial is testing a special radiation treatment called iopofosine I 131 in patients with hard-to-treat B-cell cancers. These patients have not responded well to other treatments. The treatment works by using a radioactive substance that targets and kills cancer cells.
Trials With No Placebo
Antibiotic
Rifaximin for Monoclonal Gammopathy
Recruiting3 awardsPhase 1
Atlanta, Georgia
This trial studies how well rifaximin, an oral antibiotic, works in treating patients with monoclonal gammopathy. It aims to reduce abnormal blood proteins or cells by killing intestinal bacteria. Rifaximin has been used successfully for CDI treatment but lacks United States Food and Drug Administration approval for this indication.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Oral LOXO-305 for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is testing pirtobrutinib, a tablet taken by mouth, in patients with certain types of blood cancers who haven't responded to or can't tolerate usual treatments. The medication works by blocking a protein that cancer cells need to grow. The study aims to find the best dose and see how well it works.
Enzyme Inhibitor
Ibrutinib + Ixazomib for Waldenstrom's Macroglobulinemia
Recruiting3 awardsPhase 2
Jacksonville, Florida
This trial looks at the side effects of two drugs, ibrutinib and ixazomib, when given together to treat Waldenstrom macroglobulinemia. Enzyme inhibitors, such as ibrutinib and ixazomib, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Stem Cell Transplant + Chemotherapy for Leukemia and Lymphoma
Recruiting1 awardPhase 1 & 2
Buffalo, New York
This trial is studying how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant.
BTK Inhibitor
Nemtabrutinib for Blood Cancers
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing a new pill called nemtabrutinib for patients with blood cancers that have returned or didn't respond to other treatments. The goal is to find a safe and effective dose of the drug. Nemtabrutinib is a new drug being tested for blood cancers, designed to reduce adverse effects.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.